The method, presented at the European Congress of Clinical Microbiology and Infectious Diseases, may provide results in hours rather than a week or more.
Industry executives said that clinical needs associated with antimicrobial resistance and sepsis are generating more interest in AST technologies.
Specific Diagnostics said that the CARB-X funding will enable it to prepare its AST instrument for clinical trials and regulatory validation.
The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.
Since moving to rapid molecular testing, the lab has doubled its billable test volume, largely through increasing clients for its outreach lab services.
The Boston-based startup will use the funds to expedite prototype development of its sample preparation technology and computational approach.
The firm had also applied for marketing clearance for its gram negative and fungal pathogen panels in October.
The company is developing a new gold standard comparator test after it encountered problems with typical culture methods it used in developing a new pneumonia assay.
The FDA cleared BD's test for detecting carbapenemase-producing organisms, which can be used by hospitals to contain the spread of antimicrobial resistance.
The firm signed four new distribution deals to spread its products into more than a dozen new markets.